Number of pages: 100 | Report Format: PDF | Published date: March 02, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
Report Attribute |
Details |
Market Size Value in 2022 |
US$ 47.6 million |
Revenue Forecast in 2031 |
US$ 139.8 million |
CAGR |
12.7% |
Base Year for Estimation |
2022 |
Forecast Period |
2023-2031 |
Historical Year |
2021 |
Segments Covered |
Therapy, End-user, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global synovial sarcoma therapeutics market was valued at US$ 47.6 million in 2022 and is expected to register a revenue CAGR of 12.7% to reach US$ 139.8 million by 2031.
Synovial Sarcoma Therapeutics Market Fundamentals
Synovial sarcoma is a rare cancer type originating from various types of soft tissues, including muscles, ligaments, and tendons. It frequently develops in the arm, limb, or foot, and near joints, such as the wrist or ankle. It can also arise in the soft tissues of the abdomen or lungs. Malignant synovioma is another name for synovial sarcoma. A deep-seated lump that may be hypersensitive or painful is the first indication of a health issue. The growth of synovial sarcoma is gradual.
Although these tumors can develop in young children, most individuals between the ages of 15 and 40 are susceptible to this type of cancer. Synovial sarcoma makes up 5% to 10% of soft tissue sarcoma. In the United States, one to two cases of synovial sarcoma are identified in every million individuals annually. Synovial sarcoma can develop various symptoms depending on the location of the tumor. A lump with no discomfort is often the first symptom of synovial sarcoma. As it grows, it may produce pain or numbness if it is close to a nerve. The mainstay of treatment for synovial sarcoma is surgery. Other than that, the recent developments in immunotherapy alone or in combination are commonly used to treat synovial sarcoma. The target is to eliminate the malignancy along with a margin of healthy tissues. This may occasionally entail amputating a leg or even removing an entire muscle or set of muscles. The doctor might advise a regimen of radiation treatment or chemotherapy in addition to surgery to lessen the possibility of recurrence.
[7685768]
Synovial Sarcoma Therapeutics Market Dynamics
Over the past few decades, there has been an increase in the incidence rate of all cancer types. In addition to contributing to 70% of all cancer mortality globally, Africa, Asia, Central America, and South America also account for more than 60% of all new cancer cases. According to the World Health Organization (WHO), cancer reports 8.3 million deaths annually, and 70% more new cancer cases are projected to be reported over the next 20 years. At the same time, synovial sarcoma is estimated to occur 2.75 times per 100,000 people. The lower limbs are involved in most cases. About 800 new instances of this tumor are reported annually in the United States, accounting for 5% to 10% of all soft-tissue sarcomas. The most important risk factors are exposure to certain chemicals, previous cancer treatment, unhealthy lifestyle, along with the consumption of alcohol and tobacco. Therefore, the high prevalence of cancer is the major driving factor for the global synovial sarcoma therapeutics market.
Strong emphasis on research and development to improve a range of treatment options, including monoclonal antibodies and targeted therapies, boosts revenue growth in the global synovial sarcoma therapeutics market. Additionally, a robust clinical pipeline is expected to drive the market in the near future. Several therapeutics are in the pipeline for the treatment of synovial sarcoma, some of which are currently undergoing phase III clinical trials. Moreover, promising outcomes are being observed with cutting-edge technologies, such as ZVex and GLASS, RESOLYSIN, and tumor-specific cytotoxic T-cell therapy. Therefore, a substantial drug pipeline and rising consumer knowledge are the main factors propelling market revenue growth. As a result of the increasing demand for pioneering treatment modalities among patients with multiple cancer types, the grants for cancer research have increased over the past few years. The National Institutes of Health increased its funding for studies based on cancer treatment by more than 5% year over year in 2018, achieving its highest level. Growing demand for non-conventional treatment choices is the primary factor driving market expansion. The usage of regenerative medicine enables patients to resume normal activities as soon as possible by speeding up the healing process for patients compared to standard care. Increased demand for personalized medicine is driving revenue growth in the global synovial sarcoma therapeutics market.
However, the side effects associated with synovial sarcoma treatment and the high cost of treatment are the major restraining factors for the global synovial sarcoma therapeutics market. For instance, research carried out in December 2022 at Cuautitlán Izcalli estimated the total medical cost of illness of synovial sarcoma at the National Institute of Cancerology (Mexico City) in the last ten years (2010-2021) was an average of US$ 2823. Also, stringent government regulations and the high failure in clinical trials may hamper market development in the future. For instance, in November 2018, the clinical phase III trial by Immune Design Corp. to assess if the CMB305 vaccine regimen may help the body’s immune system slow or stop synovial sarcoma growth tumor and improve survival was terminated as it could not meet the efficacy level.
Synovial Sarcoma Therapeutics Market Ecosystem
The global synovial sarcoma therapeutics market is analyzed from three perspectives: therapy, end-user, and region.
Synovial Sarcoma Therapeutics Market by Therapy
[856756]
Based on the therapy, the global synovial sarcoma therapeutics market is segmented as anti-angiogenesis drugs and chemotherapy.
The anti-angiogenesis drugs segment accounted for the largest revenue share of the global synovial sarcoma therapeutics market in 2022. Anti-angiogenesis drugs, also known as angiogenesis inhibitors, are unique cancer-fighting substances as they prevent the development of blood vessels that promote tumor growth rather than the growth of tumor cells. Some commonly used, FDA-approved anti-angiogenesis drugs for the treatment of soft tissue sarcoma, including synovial sarcoma, are olaratumab, pazopanib, imatinib, sunitinib, sorafenib, regorafenib. Anti-angiogenesis drugs have gained considerable attention and are currently one of the most effective methods to treat cancer, owing to their higher efficacy and survival rate. Tyrosine kinase inhibitors are the most significant category of anti-angiogenesis drugs. Tyrosine kinase inhibitors have fewer or different adverse effects than cytotoxic chemotherapeutic drugs, appear to stabilize tumor progression in a variety of tumor types, and are frequently synergistic with radiotherapy or chemotherapy. Therefore, anti-angiogenesis drugs are administered as a first line of treatment in synovial sarcoma.
The chemotherapy segment is anticipated to account for a sizable revenue share of the global synovial sarcoma therapeutics market during the forecast period. The first-line treatment for synovial sarcoma can be either single-agent or combined chemotherapy. Anthracycline antibiotic doxorubicin is generally regarded as the most effective single agent generating objective responses in clinical trial settings. First-line chemotherapy for managing synovial sarcoma continues to be primarily based on doxorubicin, either with or without ifosfamide. However, data from new studies indicate that patients with synovial sarcoma may benefit more from ifosfamide and doxorubicin combination therapy than doxorubicin monotherapy.
With promising results, immunotherapy is an emerging treatment for various cancer types. According to studies conducted at the cellular level, some sarcoma subtypes have comparatively high immunogenicity. Therefore, the adoption of immunotherapy is rapidly increasing to treat rare soft tissue sarcomas, such as synovial sarcoma, effectively.
Synovial Sarcoma Therapeutics Market by End-user
Based on the end-user, the global synovial sarcoma therapeutics market is segmented into hospitals, specialty clinics, oncology centers, and others.
The hospitals segment accounted for the largest revenue share of the global synovial sarcoma therapeutics market in 2022. The market has taken the lead as hospitals have more financial assistance to invest in advanced innovative care. Hospitals are the best option for treatment as they have the required medications to offer patients comprehensive care. The rising prevalence of cancers, expanding access to healthcare reimbursements in many developed countries, and ongoing industrial advancements in regenerative therapeutics are the major drivers for segment growth. Multispecialty hospitals can be helpful in treating multiple ailments simultaneously. The presence of a group of physicians, surgeons, and other skilled healthcare professionals makes the treatment procedure easier. Additionally, sufficient funds enable the hospitals to have advanced newly launched treatment options and cost-effective diagnostics. As a result, irrespective of income, patients can easily rely on hospitals for treatments.
Synovial Sarcoma Market by Region
Based on the region, the global synovial sarcoma therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America accounted for the largest revenue share of the global synovial sarcoma therapeutics market in 2022. The high prevalence of soft tissue sarcoma and synovial sarcoma in North America is the major driver for market growth in this region. The American Cancer Society estimated that in 2023, there would be about 13,400 new cases of soft tissue sarcomas diagnosed in the country (7,400 in men and 6,000 in women) and that there will be about 5,140 deaths from soft tissue sarcomas, including synovial sarcoma, affecting 2,720 men and 2,420 women. Moreover, the development of invasive treatments, current FDA approval, and an increase in the adoption of novel approaches by patients and physicians are the main factors that have fueled the North America synovial sarcoma therapeutics market revenue growth. Another important reason for expanding the North America synovial sarcoma market is the development of novel therapies and treatments for the disease, owing to increased funding from the Sarcoma Foundation of America and Synovial Sarcoma Research Foundation. A rise in the number of elderly and obese people is anticipated to lead to an increase in the number of patients, fueling market expansion in the region.
The synovial sarcoma market in Europe is also growing owing to the increase in the incidence of synovial sarcoma and the rise in research and development activities for cancer treatment.
Synovial Sarcoma Therapeutics Market Competitive Landscape
The prominent players in the synovial sarcoma market are:
Synovial Sarcoma Therapeutics Market Strategic Developments
Synovial sarcoma is a rare cancer that can originate from various soft tissues, including muscles, ligaments, and tendons. Anti-angiogenesis drugs, immunotherapy, and chemotherapy alone or in combination are utilized to treat synovial sarcoma.
Increased incidence of synovial sarcoma and developed research on oncology are key trends governing the global synovial sarcoma therapeutics market.
Hoffmann-La Roche Ltd., Bayer AG, Eisai Pharmaceuticals Pvt Ltd., Eli Lilly and Company, and Cue Biopharma are among the top market players.
The high cost and post-treatment adversities are the main restraining factors for the global synovial sarcoma therapeutics market.
The global synovial sarcoma therapeutics market is expected to grow at a revenue CAGR of 12.7% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain